Evaluation of a New Preparation of Urokinase

Summary

The pharmacological effect of a new preparation of urokinase (Leo) has been studied, both in vitro and in six patients suffering from thrombo-embolic disorders. It was a non-toxic, effective fibrinolytic agent if given in sufficient dosage. A regimen consisting of an initial dose of 7,200 ploug units per kg body weight, followed by hourly maintenance therapy with 3,600 ploug units per kg intravenously, gave satisfactory evidence of whole body fibrinolytic activity. The preparation had minor but insignificant thromboplastic activity both when assayed in the laboratory and when given to patients.

^* Present position: Professor of Medicine, The General Infirmary, Leeds.

• References

• 1 Alkjaersig N, Fletcher A. P, and Sherry S. 1965; The assay of urokinase preparations for contamination with thromboplastic moieties. Journal of Laboratory and Clinical Medicine 65: 732.
• 2 Breckeneidge R.T, and Ratnoff O. D. 1962; Studies on the nature of the circulating anticoagulant directed against antihaemophilic factor: with notes on an assay for antihaemophilic factor’. Blood 20: 137.
• 3 Davis B.J. 1964; Disc-electrophoresis, part II. Method and application to human serum proteins. Annals of the New York Academy of Science 121: 404.
• 4 Dubber A. H. C, McNicol G. P, Wilson P. A, and Douglas A. S. 1967; Studies with a preparation of urokinase. Thrombosis et Diathesis Haemorrhagica (Stuttg.) 18: 133.
• 5 Duckert F. 1968. Urokinase. In: Dubach IT. C. (ed.) Enzymes in urine and kidney. Hans Huber; Bern,: 237.
• 6 Fletcher A. P, Alkjaersig N, and Sherry S. 1959; The maintenance of a sustained thrombolytic state in man. 1. Induction and effects. Journal of Clinical Investigation 38: 1096.
• 7 Fletcher A. P, Alkjaersig N, Sherry S, Genton E, Hirsh J, and Bachman F. 1965; The development of urokinase as a thrombolytic agent. Journal of Laboratory and Clinical Medicine 65: 713.
• 8 McNicol G.P, Gale S.P, and Douglas A.S. 1963; In vitro and in vivo studies of a preparation of urokinase. British Medical Journal 1: 909.
• 9 McNicol G.P, and Douglas A.S. 1964. The fibrinolytic enzyme system. In: Dyke S. C. Recent advances in Clinical Pathology. Series IV; Churchill, London,: 205.
• 10 Merskey C, Kleiner C.J, and Johnson A.J. 1966; Quantitative estimation of split products of fibrinogen in human serum, relationship to diagnosis and treatment. Blood 28: 1.
• 11 Nilsson I. M, and Olow B. 1962; Fibrinolysis induced by streptokinase in man. Acta Medica Scandinavica 123: 247.
• 12 Ornstein L. 1964; Disc-electrophoresis. Background and theory. Annals of the New York Academy of Science 121: 321.
• 13 Ploug J, and Kjeldgaard N. O. 1957; Urokinase. An activator of plasminogen from human urine. I. Isolation and properties. Biochemica et Biophysica Acta (Amst.) 24: 278.
• 14 Prentice C. R. M, Turpie A. G. G, McNicol G. P, and Douglas A. S. 1972; Urokinase therapy: dosage schedules and coagulant side effects. British Journal of Haematology 22: 567.
• 15 Ratnoff O. D, and Menzie C. 1951; A new method for the determination of fibrinogen in small samples of plasma. Journal of Laboratory and Clinical Medicine 31: 316.
• 16 Remmert L. F, and Cohen P. P. 1949; Partial purification and properties of a proteolytic enzyme of human serum. Journal of Biological Chemistry 181: 143.
• 17 Sweet B, McNicol G.P, and Douglas A.S. 1965; In vitro studies of staphylokinase. Clinical Science 29: 373.